Oncimmune Holdings (UK) Today
| ONC Stock | 14.80 0.55 3.58% |
Performance0 of 100
| Odds Of DistressOver 88
|
Oncimmune Holdings is trading at 14.80 as of the 29th of November 2024, a 3.58 percent decrease since the beginning of the trading day. The stock's lowest day price was 14.6. Oncimmune Holdings has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Oncimmune Holdings plc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of June 2023 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Oncimmune Holdings is entity of United Kingdom. It is traded as Stock on LSE exchange. The company has 111.77 M outstanding shares. More on Oncimmune Holdings plc
Moving together with Oncimmune Stock
Moving against Oncimmune Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Oncimmune Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Oncimmune Holdings' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Oncimmune Holdings or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Director | Adam Hill | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
Oncimmune Holdings' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Oncimmune Holdings' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsOncimmune Holdings can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Oncimmune Holdings' financial leverage. It provides some insight into what part of Oncimmune Holdings' total assets is financed by creditors.
| |||||
Oncimmune Holdings plc (ONC) is traded on London Exchange in UK and employs 38 people. Oncimmune Holdings is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.54 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Oncimmune Holdings's market, we take the total number of its shares issued and multiply it by Oncimmune Holdings's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Oncimmune Holdings plc operates under Biotechnology sector and is part of Health Care industry. The entity has 111.77 M outstanding shares.
Oncimmune Holdings generates negative cash flow from operations
Check Oncimmune Holdings Probability Of Bankruptcy
Ownership AllocationOncimmune Holdings owns a total of 111.77 Million outstanding shares. Oncimmune Holdings has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Oncimmune Ownership Details
Oncimmune Holdings plc Risk Profiles
Although Oncimmune Holdings' alpha and beta are two of the key measurements used to evaluate Oncimmune Holdings' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.52 | |||
| Standard Deviation | 4.64 | |||
| Variance | 21.55 | |||
| Risk Adjusted Performance | (0.03) |
Oncimmune Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Oncimmune Holdings without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Balance Of Power Now
Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios |
| All Next | Launch Module |
Oncimmune Holdings Corporate Management
Elected by the shareholders, the Oncimmune Holdings' board of directors comprises two types of representatives: Oncimmune Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncimmune. The board's role is to monitor Oncimmune Holdings' management team and ensure that shareholders' interests are well served. Oncimmune Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncimmune Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shane Smith | VP Oncimmune | Profile | |
| BA FCA | Exec | Profile | |
| BSc FRCP | Chief Officer | Profile | |
| James MD | Chief US | Profile | |
| Maarten Brusse | Chief Asia | Profile |
Other Information on Investing in Oncimmune Stock
Oncimmune Holdings financial ratios help investors to determine whether Oncimmune Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncimmune with respect to the benefits of owning Oncimmune Holdings security.